These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25518340)

  • 21. The roles of microRNAs in the progression of castration-resistant prostate cancer.
    Kojima S; Goto Y; Naya Y
    J Hum Genet; 2017 Jan; 62(1):25-31. PubMed ID: 27278789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
    Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
    Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
    Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
    J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor (AR) aberrations in castration-resistant prostate cancer.
    Waltering KK; Urbanucci A; Visakorpi T
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):38-43. PubMed ID: 22245783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.
    Gsponer JR; Braun M; Scheble VJ; Zellweger T; Bachmann A; Perner S; Vlajnic T; Srivastava M; Tan SH; Dobi A; Sesterhenn IA; Srivastava S; Bubendorf L; Ruiz C
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):126-31. PubMed ID: 24469092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.
    Jian J; Wang X; Zhang J; Zhou C; Hou X; Huang Y; Hou J; Lin Y; Wei X
    Front Endocrinol (Lausanne); 2024; 15():1360430. PubMed ID: 38887275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.
    Xu D; Zhan Y; Qi Y; Cao B; Bai S; Xu W; Gambhir SS; Lee P; Sartor O; Flemington EK; Zhang H; Hu CD; Dong Y
    Cancer Res; 2015 Sep; 75(17):3663-71. PubMed ID: 26060018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical phenotypes of castration-resistant prostate cancer.
    Zhang T; Armstrong AJ
    Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
    Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of BET proteins in castration-resistant prostate cancer.
    Fernandez-Salas E; Wang S; Chinnaiyan AM
    Drug Discov Today Technol; 2016 Mar; 19():29-38. PubMed ID: 27769354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
    Valdez CD; Kunju L; Daignault S; Wojno KJ; Day ML
    Prostate; 2013 Dec; 73(16):1776-85. PubMed ID: 24038143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer].
    Wang B; Wu KJ; He DL
    Zhonghua Nan Ke Xue; 2013 Aug; 19(8):736-41. PubMed ID: 24010211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
    Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
    Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6).
    Liu D; Tao T; Xu B; Chen S; Liu C; Zhang L; Lu K; Huang Y; Jiang L; Zhang X; Huang X; Zhang L; Han C; Chen M
    Biochem Biophys Res Commun; 2014 Feb; 445(1):151-6. PubMed ID: 24491557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hallmarks of castration-resistant prostate cancers.
    Katsogiannou M; Ziouziou H; Karaki S; Andrieu C; Henry de Villeneuve M; Rocchi P
    Cancer Treat Rev; 2015 Jul; 41(7):588-97. PubMed ID: 25981454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative RNA-seq analysis reveals potential mechanisms mediating the conversion to androgen independence in an LNCaP progression cell model.
    Wang Y; Wang Y; Liu Q; Xu G; Mao F; Qin T; Teng H; Cai W; Yu P; Cai T; Zhao M; Sun ZS; Xie C
    Cancer Lett; 2014 Jan; 342(1):130-8. PubMed ID: 24012641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.
    Shiota M; Yokomizo A; Naito S
    J Mol Endocrinol; 2011 Aug; 47(1):R25-41. PubMed ID: 21504942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer.
    Rocha J; Zouanat FZ; Zoubeidi A; Hamel L; Benidir T; Scarlata E; Brimo F; Aprikian A; Chevalier S
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):140-9. PubMed ID: 23906537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.